Research programme: Alzheimer's disease therapies - Siena Biotech

Drug Profile

Research programme: Alzheimer's disease therapies - Siena Biotech

Alternative Names: SEN 12333; SEN 34625; WAY-317538; WYE-103914

Latest Information Update: 27 Sep 2011

Price : $50

At a glance

  • Originator Siena Biotech
  • Class Small molecules
  • Mechanism of Action Alpha7 nicotinic acetylcholine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease

Most Recent Events

  • 21 Oct 2009 Preclinical pharmacodynamics data presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009) ,
  • 16 Oct 2009 Wyeth has been acquired by Pfizer
  • 20 Nov 2007 Pharmacodynamics data from a preclinical study presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007) have been added to the Psychotic disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top